The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,246.00
Bid: 12,254.00
Ask: 12,256.00
Change: -72.00 (-0.58%)
Spread: 2.00 (0.016%)
Open: 12,324.00
High: 12,406.00
Low: 12,246.00
Prev. Close: 12,318.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET OPEN: RBS And Just Eat Slip; Computacenter Climbs

Fri, 26th Apr 2019 08:42

LONDON (Alliance News) - Stock prices in London opened in the red on Friday, with Royal Bank of Scotland slipping after a drop in income and a warning over the impact of Brexit.Elsewhere, Just Eat dipped after a softer than hoped performance in the UK, while Ferrexpo slumped in the FTSE 250 after its auditor quit amid an investigation into charity payments. The FTSE 100 was down 23.81 points, or 0.3%, at 7,410.32 in early trade. The FTSE 250 index was down 11.55 points, or 0.1%, at 19,859.5, while the AIM All-Share was 0.1% higher at 966.The Cboe UK 100 index was down 0.4% at 12,555.53. The Cboe UK 250 was 0.2% at 17,741.84, and the Cboe UK Small Companies was up 0.1% at 11,626.1.On the London Stock Exchange, RBS sat at the bottom of the FTSE 100, down 5.1%, after it reported a decreased profit in the first quarter on lower income and warned Brexit could continue to harm the lender's income growth.The UK government controlled bank's operating pretax profit in the three months ended March decreased 17% to GBP1.01 billion from GBP1.21 billion the year before. RBS's profit attributable to shareholders slipped 13% to GBP707 million.RBS attributed the decreased quarterly profit to lower income.RBS's first quarter total income fell 7.9% to GBP3.04 billion from GBP3.30 billion year-on-year, with net-interest income declining 5.6% to GBP2.03 billion from GBP2.15 billion.The lender's cost-to-income ratio edged up to 63.4% in the quarter compared to 60.5% the year prior. RBS' CET1 ratio at the end of March was 16.2%, down from 16.4% at the end of the first quarter a year ago. At the end of 2018, RBS's CET1 ratio stood at 16.2%.The bank's net interest margin in the first quarter was 1.89% versus 2.04% in the first quarter of 2018. In the fourth quarter of 2018, RBS's NIM was 1.95%."This morning's first quarter update from RBS has been overshadowed somewhat by yesterday's news Chief Executive Ross McEwan will be leaving the business in the next 12 months; however the numbers do illustrate how much the bank has moved on from when he took up the position all the way back in 2013," said CMC Markets UK's Michael Hewson.Online takeaway food platform Just Eat fell 4.2%, as it reported a 21% rise in orders for the first quarter of 2019 to 61.4 million, with revenue up 28% to GBP227.9 million.Just Eat's UK orders rose 7.3% to 31.9 million, but performance was not as good as expected, hurt by a strong comparative, unusually warm weather in February, and the Easter break entirely falling in the second quarter.Outside of the UK, orders surged 40%, helped by strong growth in Canada, Italy, Switzerland, and Ireland.Guidance for 2019 is once again reiterated, with Just Eat seeing revenue between GBP1.0 billion and GBP1.1 billion and underlying earnings before interest, tax, depreciation, and amortisation of GBP185 million to GBP205 million.Miner Glencore slipped 3.4% after reporting late Thursday the US Commodity Futures Trading Commission has launched an investigation into whether the commodities trader has violated provisions of the Commodities Exchange Act.The investigation is currently at an early stage and follows a similar scope to the ongoing investigation by the US Department of Justice. Glencore said it will cooperate with the Commission's investigation.Advertising firm WPP was down 1.0%, despite a slight rise at the open, as it said it is making good progress, with first quarter revenue up 0.9% at reported currency to GBP3.59 billion. Excluding currency movements, revenue was down 0.6%, and like-for-like it fell 1.3%.Like-for-like revenue minus pass-through costs in North America fell 8.5%, making it WPP's weakest performing region, due to continued losses among automotive, pharmaceutical, and fast-moving consumer goods clients.UK like-for-like revenue less pass-through costs fell 0.9%, slightly worse than the year ago period, while the figure fell 0.3% in Western Continental Europe.WPP's like-for-like revenue less pass-through costs elsewhere rose 2.3%, with strong growth in the Latin America, Central & Eastern Europe, and South East Asia segments.WPP has reiterated guidance for 2019, targeting a fall in like-for-like less pass-through costs revenue of 1.5% to 2.0%.AstraZeneca rose just 0.1% as it reported a solid set of first quarter results, with new medicines helping drive growth in product sales.AstraZeneca's product sales climbed 10% for the first three months of 2019 to USD5.47 billion, with constant currency growth 14%. Revenue was up 6%, or 11% constant currency, to USD5.49 billion.Pretax profit doubled to USD758 million, with reported operating profit rising 58% at actual currency rates to USD1.10 billion and core operating profit up 84% at actual rates to USD1.65 billion.Looking within products, Oncology sales rose 54% to USD1.89 billion, New Cardiovascular, Renal, & Metabolism sales rose 15% to USD1.03 billion, and Respiratory sales climbed 9% to USD1.28 billion.pressure.Emerging markets as a segment posted 14% growth to USD2.00 billion, with Chinese sales up 21%.Looking ahead, AstraZeneca has reiterated all 2019 guidance, including for high single-digit growth in product sales.In the FTSE 250, Computacenter surged 12%, with first-quarter revenue and profit ahead year-on-year, before the "positive" impact of acquisitions. This is above expectations, given a tough comparative year-on-year.The UK saw revenue growth despite a large one-off deal a year prior, while US also achieved revenue growth on a like-for-like basis.Looking ahead, Computacenter is "firmly" on track to meet 2019 expectations, and confidence has increased following the first quarter performance.Stagecoach also rose, climbing 3.8%, after Citigroup raised its rating on the stock to Buy from Neutral. Iron ore pellet maker Ferrexpo slumped 14%. Auditor Deloitte has resigned with immediate effect, the company announced.The company recently published long-delayed 2018 results amid an investigation into payments to a charity in Ukraine.Insurer Hastings fell 5.1%, reporting a 4% rise in gross written premiums to GBP235.5 million for the first quarter, with live customer policies up 3% to 2.75 million. Net revenue fell 1% to GBP183.1 million.Looking ahead, Hastings said if current market premium and claims dynamics continue through the remainder its loss ratio for 2019 will be towards the upper end of its 75% to 79% target range.Hastings also confirmed new Chief Financial Officer John Worth will join on May 10.Wall Street ended mixed in the US on Thursday following the continuation of its own earnings season, with the Dow Jones Industrial Average closing 0.5% lower, the S&P 500 marginally lower, but the Nasdaq Composite up 0.2%.SPI Asset Management's Steve Innes said: "US markets traded mixed as the latest earnings reports sent investors scurrying every which way but higher as big tech heavyweight gains were neutralised by industrial stalwarts whose sector shares tracked lower."But adding to top side pressures is the uniform move covering a breadth of cross-asset markets which suggest investors are starting to weave yet another cautionary tale as global growth concern continue to mount."The Japanese Nikkei 225 index ended down 0.3% Friday. In China, the Shanghai Composite closed 0.8% down, while the Hang Seng index in Hong Kong is flat in late trade. The economic calendar has UK BBA mortgage approval figures at 0930 BST and US first-quarter GDP at 1330 BST."Economists are expecting a reading of 2.1%. The figure will be closely watched as the Federal Reserve lowered its growth forecast for 2019 to 2.1%, from the 2.3% projection in December," said CMC Markets UK's David Madden."The US central bank have dropped a big hint interest rates are likely to hold steady for the foreseeable future, but they have also given themselves the wiggle room for a hike, should the economy outperform."

More News
14 Nov 2023 09:22

AstraZeneca's latest lung cancer trial fails its primary endpoint

(Sharecast News) - AstraZeneca announced on Tuesday that its 'PACIFIC-2' phase three trial for Imfinzi, or durvalumab, concurrently administered with chemoradiotherapy (CRT), did not achieve its primary endpoint of progression-free survival compared to CRT alone.

Read more
13 Nov 2023 09:45

LONDON BROKER RATINGS: Diageo gets price target cuts; JPMorgan ups M&G

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning:

Read more
9 Nov 2023 15:02

London close: Stocks gain as investors await Powell speech

(Sharecast News) - London's stock markets were buoyant at the close of trading on Thursday, influenced by Chinese inflation data, a substantial influx of corporate news, and a speech from the Fed chair later in the global day.

Read more
9 Nov 2023 12:06

LONDON MARKET MIDDAY: FTSE up despite higher for longer US rates fear

(Alliance News) - European equities were on the up on Thursday, despite lingering US interest rate worries and poor China data.

Read more
9 Nov 2023 11:02

Lancashire Holdings declares special dividend after strong year so far

(Alliance News) - Lancashire Holdings Ltd on Thursday said it approved a capital return of up to USD169 million, and it reported rising gross premiums written for the year-to-date.

Read more
9 Nov 2023 09:23

TOP NEWS: AstraZeneca ups guidance; inks licence deal for obesity drug

(Alliance News) - AstraZeneca PLC on Thursday announced that it signed a contract for an obesity drug as it reported a higher pretax profit in the third quarter of 2023, boosted by cancer drug conjugate Enhertu.

Read more
9 Nov 2023 08:57

LONDON MARKET OPEN: FTSE 100 kicks off day with cautious gain

(Alliance News) - London's FTSE 100 struggled for direction early Thursday, with a mixed slate of corporate updates, US interest rate worries and underwhelming China data preventing it from making more confident progress in early trade.

Read more
9 Nov 2023 07:48

LONDON BRIEFING: AstraZeneca ups outlook but S4 Capital cuts

(Alliance News) - London's FTSE 100 is set for another downbeat start to the day, with more hawkish comments from US central bankers and tepid data out of China doing little to lift the mood.

Read more
9 Nov 2023 07:18

AstraZeneca hikes guidance after strong third quarter

(Sharecast News) - AstraZeneca released its financial results for the third quarter and first nine months of 2023 on Thursday, hiking its full-year guidance on the back of a robust performance and momentum in several segments.

Read more
3 Nov 2023 17:06

AstraZeneca plans next phase of trial on kidney drug combination data

(Alliance News) - AstraZeneca PLC on Friday touted results from a Phase IIb trial, which showed that a zibotentan and dapagliflozin combination demonstrated significant albuminuria reduction in patients with chronic kidney disease and proteinuria.

Read more
3 Nov 2023 11:34

AstraZeneca's Lokelma lets kidney disease patients maintain therapy

(Alliance News) - AstraZeneca PLC on Thursday celebrated results from an observational study, which showed that treating hyperkalaemia with the potassium binder, Lokelma, allows chronic kidney disease and heart failure patients to maintain RAASi therapy.

Read more
2 Nov 2023 15:57

UK earnings, trading statements calendar - next 7 days

Friday 3 November 
no events scheduled 
Monday 6 November 
Kingspan Group PLCTrading Statement
Kosmos Energy LtdQ3 Results
Ryanair Holdings PLCHalf Year Results
Tuesday 7 November 
Associated British Foods PLCFull Year Results
Beazley PLCQ3 Results
Direct Line Insurance Group PLCTrading Statement
dotdigital Group PLCFull Year Results
IWG PLCQ3 Results
Persimmon PLCTrading Statement
RS Group PLCHalf Year Results
Vaalco Energy IncQ3 Results
Watches of Switzerland Group PLCTrading Statement
Wednesday 8 November 
Conduit Holdings LtdQ3 Results
ITV PLCTrading Statement
JD Wetherspoon PLCQ1 Results
Marks & Spencer Group PLCHalf Year Results
MaxCyte IncQ3 Results
Secure Trust Bank PLCTrading Statement
Smiths News PLCFull Year Results
Time Out Group PLCFull Year Results
Thursday 9 November 
3i Group PLCHalf Year Results
Apax Global Alpha LtdQ3 Results
AstraZeneca PLCQ3 Results
Auto Trader Group PLCHalf Year Results
B&M European Value Retail SAHalf Year Results
Domino's Pizza Group PLCTrading Statement
Endeavour Mining PLCQ3 Results
Flutter Entertainment PLCTrading Statement
IMI PLCTrading Statement
Indivior PLCQ3 Results
John Wood Group PLCTrading Statement
Lancashire Holdings LtdTrading Statement
National Grid PLCHalf Year Results
Regional REIT LtdTrading Statement
Renewi PLCHalf Year Results
S4 Capital PLCTrading Statement
Tate & Lyle PLCHalf Year Results
Taylor Wimpey PLCTrading Statement
TBC Bank Group PLCQ3 Results
TheWorks.co.uk PLCTrading Statement
Trakm8 Holdings PLCHalf Year Results
Urban Logistics REIT PLCHalf Year Results
Vistry Group PLCTrading Statement
WH Smith PLCFull Year Results
Wincanton PLCHalf Year Results
Wizz Air Holdings PLCHalf Year Results
  
Copyright 2023 Alliance News Ltd. All Rights Reserved.

Read more
1 Nov 2023 08:59

AstraZeneca launches collaboration and investment deal with Cellectis

(Alliance News) - AstraZeneca PLC on Wednesday announced a new collaboration and investment agreement with clinical-stage biotechnology company Cellectis.

Read more
1 Nov 2023 07:33

AstraZeneca invests $220m in French gene-editing group Cellectis

(Sharecast News) - AstraZeneca is to invest in French biopharma group Cellectis to use its gene-editing technologies to develop next-gen therapeutics in areas like oncology, immunology and rare diseases.

Read more
30 Oct 2023 09:40

LONDON BROKER RATINGS: Jefferies cuts NatWest to underperform from buy

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.